Across TCGA pan-cancer cohorts, ACTBP11 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ACTBP11’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ACTBP11 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACTBP11 is over-expressed in tumor, although a few such as HNSC and PAAD show the opposite, repressed pattern.
LIHC, COAD, and BRCA are the cancer types where ACTBP11 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTBP11 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.